Mirum Q2 revenue rises 64%, raises 2025 guidance

Mirum Pharmaceuticals

06/08/2025 21:10

Overview

Mirum Q2 2025 revenue grows to $128 mln, driven by Livmarli sales

Company raises 2025 revenue guidance to $490-$510 mln

Mirum reports Q2 net loss of $5.9 mln despite revenue growth

Outlook

Mirum raises 2025 revenue guidance to $490-$510 mln

Company expects Volixibat VISTAS study topline data in Q2 2026

Mirum plans Phase 2 MRM-3379 study in Fragile X Syndrome in Q4 2025

Result Drivers

LIVMARLI SALES - Livmarli net product sales reached $88.2 mln, marking an 87% growth over Q2 2024

INTERNATIONAL SUCCESS - Strong performance from international business and U.S. PFIC launch contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$127.78 mln
Q2 Net Income
-$5.86 mln
Q2 Basic EPS
-$0.12
Q2 Operating Expenses
$132.77 mln
Q2 Operating Income
-$4.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $73.00, about 29% above its August 5 closing price of $51.84

Press Release: ID:nBwZ0m9ta

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)